NeuroPace, Inc. Announces Preliminary, Unaudited Revenue Guidance for the Fourth Quarter and Full-Year Ended December 31, 2021
January 11, 2022 at 04:03 pm EST
Share
NeuroPace, Inc. announced its preliminary, unaudited revenue guidance for the fourth quarter and full-year ended December 31, 2021. For the quarter, the company expected preliminary unaudited revenue to be approximately $11.0 million, compared to $10.8 million in the fourth quarter in the prior year period, reflecting growth of 2%.
For the year, the company expected preliminary unaudited revenue to be approximately $45.2 million, compared to $41.1 million in full year 2020, reflecting growth of 10%.
NeuroPace, Inc. is a medical device company. The Company is focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is a brain-responsive platform that delivers personalized, real-time treatment at the seizure source. The Company has developed its RNS System to address the individualized nature of drug-resistant epilepsy and deliver a safe therapy for focal onset seizures anywhere in the brain. The RNS System is a device that records brain activity data and allows clinicians to monitor patients not only in person, but also remotely. RNS System monitors and analyzes the brainâs electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Companyâs RNS System is also engaged in treating other brain disorders, including depression, impulse control disorders, memory disorders, and post-traumatic stress disorder.
NEUROPACE, INC. 
